GAMMA Investing LLC Purchases 130 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

GAMMA Investing LLC grew its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 24.3% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 665 shares of the medical research company’s stock after acquiring an additional 130 shares during the period. GAMMA Investing LLC’s holdings in Bio-Rad Laboratories were worth $218,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. First Eagle Investment Management LLC grew its stake in Bio-Rad Laboratories by 32,296.9% in the second quarter. First Eagle Investment Management LLC now owns 636,275 shares of the medical research company’s stock worth $173,773,000 after purchasing an additional 634,311 shares during the period. Principal Financial Group Inc. grew its position in shares of Bio-Rad Laboratories by 95.6% in the 3rd quarter. Principal Financial Group Inc. now owns 44,341 shares of the medical research company’s stock worth $14,836,000 after buying an additional 21,669 shares during the period. Mawer Investment Management Ltd. increased its stake in shares of Bio-Rad Laboratories by 63.0% in the 3rd quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company’s stock worth $72,900,000 after acquiring an additional 84,237 shares in the last quarter. Verition Fund Management LLC increased its stake in shares of Bio-Rad Laboratories by 193.3% in the 3rd quarter. Verition Fund Management LLC now owns 3,470 shares of the medical research company’s stock worth $1,161,000 after acquiring an additional 2,287 shares in the last quarter. Finally, Louisiana State Employees Retirement System lifted its position in Bio-Rad Laboratories by 341.7% during the 3rd quarter. Louisiana State Employees Retirement System now owns 5,300 shares of the medical research company’s stock valued at $1,773,000 after acquiring an additional 4,100 shares during the period. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Stock Performance

Shares of BIO opened at $343.88 on Wednesday. The company has a market cap of $9.63 billion, a price-to-earnings ratio of -12.58 and a beta of 0.90. The business’s fifty day simple moving average is $339.69 and its two-hundred day simple moving average is $326.68. Bio-Rad Laboratories, Inc. has a 12 month low of $262.12 and a 12 month high of $387.99. The company has a current ratio of 6.14, a quick ratio of 4.52 and a debt-to-equity ratio of 0.16.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.16 by $0.85. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The company had revenue of $649.70 million for the quarter, compared to analysts’ expectations of $628.18 million. During the same period last year, the firm posted $2.33 earnings per share. Bio-Rad Laboratories’s revenue was up 2.8% compared to the same quarter last year. Research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on BIO shares. StockNews.com upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Citigroup raised their price objective on Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Finally, Royal Bank of Canada boosted their target price on Bio-Rad Laboratories from $369.00 to $481.00 and gave the stock an “outperform” rating in a report on Monday, December 9th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Bio-Rad Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $394.20.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.